A Phase I, Randomized, Open-label, Two-Arm, Parallel Group, Single-Dose Study to Compare the Pharmacokinetics, Safety and Immunogenicity of the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects
Latest Information Update: 10 Jun 2026
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Celltrion
Most Recent Events
- 24 Feb 2026 Status changed from active, no longer recruiting to completed.
- 09 Sep 2025 Status changed from not yet recruiting to active, no longer recruiting.
- 09 Sep 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Nov 2025.